SynthesisIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026
Altered molecular signature of the intestinal microbiota in irritable bowel syndrome patients versus healthy controls: An updated systematic review.
Synthesis in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsIrritable bowel syndrome (IBS), a prevalent functional gastrointestinal disorder, poses significant challenges for both patients and medical practitioners. Recent investigations have indicated the gut microbiome as a potential therapeutic target for IBS. Nevertheless, the exact association between these microorganisms and IBS symptoms remains incompletely elucidated. This updated systematic analysis aims to assess the extant research correlating the gut microbial community with IBS.
methodsA systematic search was performed in major electronic databases including PubMed, EMBASE and Web of Science, spanning from their inception to December 2024. The objective was to identify case-control studies that examined and compared the composition of the fecal or colonic microbiota in individuals diagnosed with IBS against healthy controls.
resultsOur systematic search included 44 articles, which collectively revealed that IBS patients exhibit lower intestinal microbiome diversity compared to healthy controls. Fecal microbiome analysis demonstrated an imbalance in the phyla Firmicutes and Bacteroidetes among IBS patients. Specifically, IBS with diarrhea (IBS-D) patients showed reduced levels of Butyricimonas and Proteobacteria, while IBS with constipation (IBS-C) patients exhibited decreased Firmicutes and Actinobacteria, along with increased Verrucomicrobiota and Proteobacteria. Additionally, disruptions in the gut microbiome were noted, particularly in the duodenum and jejunum, as well as changes in key bacterial populations within the colon and rectum.
conclusionOur review confirms significant gut microbiota dysbiosis in IBS patients, characterized by reduced microbial diversity and altered abundances of Firmicutes and Bacteroidetes. These findings support the potential for microbiota-targeted therapies in IBS management, though further research is needed to establish causal mechanisms and clinical applications.
Indexed as
Identifiers
41413743What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.